Nobody Likes Rejection: Therapeutic Drug Monitoring of Mycophenolate in Solid Organ Transplant

<p>Tanner A. Melton, PharmD (Twitter <a href='https://twitter.com/TAMeltonRx'>@TAMeltonRx</a>) reviews factors associated with inter- and intra-patient mycophenolate pharmacokinetic variability, describes current strategies to perform mycophenolate therapeutic drug monitoring and determines an optimal monitoring plan for the treatment of a solid organ transplant recipient.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>